Further exploration of this novel association may potentially improve prognostication and risk stratification of children with neuroblastoma by leveraging germline genetic risk variants and may reveal therapeutic targets for aggressive MYCN‐amplified neuroblastoma. This evidence concerns the gene MYCN and neuroblastoma.